Pregabalin Misuse–Related Issues; Intake of Large Dosages, Drug-Smoking Allegations, and Possible Association With Myositis: Two Case Reports
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
To the Editors Pregabalin is a gamma-aminobutyric acid analog that is approved for the treatment of epilepsy, neuropathic pain, and generalized anxiety disorder. However, it has been anecdotally reported from the United States,1 Germany,2 Sweden,3 and Norway4 that the molecule may possess a potential of misuse. Pregabalin is widely described online by users as an “ideal psychotropic drug” for recreational purposes.5 In line with this, pregabalin has recently been included in the list of new recreational psychoactive substances officially notified to the relevant European Union agencies.6 We present here the first 2 cases of pregabalin misuse identified in southern Europe; they highlight a few related concerns, including intake of large dosages, allegations of drug smoking, and possible occurrence of myositis. CASE REPORTS Case 1 Patient 1, a 32-year-old white European, was referred to the local National Health Service outpatient drug treatment unit for issues related to pregabalin misuse. The case patient had a previous diagnosis of antisocial personality disorder and reported a history of benzodiazepines, cocaine, and ecstasy abuse. Because of a diagnosis of a neuropathic pain condition, his general practitioner started him on a pregabalin daily dosage of 75 mg 2 times a day (BD), which was then increased to 150 mg BD by day 5 and to 300 mg BD by day 12. Roughly over the following 4 weeks, however, the patient gradually increased the dosage up to an alleged daily amount of 4500 mg. He managed to get access to these levels of pregabalin tablets either through a new general practitioner’s prescription or obtaining it from a friend. At the same time, he was misusing with both alcohol and cannabis. On a few occasions, he tried to discontinue his pregabalin intake, but as a result was feeling anxious, extremely irritable, and aggressive. Conversely, in association with his pregabalin intake, he was feeling more relaxed, “more empathetic,” and with “very good drive.” He was describing his life before pregabalin initiation as “extremely boring” and characterized by constant feelings of anger. At admission, the urine toxicology specimen was positive only for cannabis. The pregabalin dosage was gradually reduced, and benzodiazepines were introduced to control the case patient’s withdrawal signs and symptoms. However, after a few days, the patient dropped out of treatment. Case 2 Patient 2, a 33-year-old white European, was referred to the local National Health Service outpatient psychiatric unit for issues related to both his bipolar and generalized anxiety disorder conditions. Because of these, he was prescribed olanzapine, 10 mg/d, and was started with pregabalin, 75 mg once a day. Pregabalin was then increased to 75 mg BD by day 3 and to 150 mg BD by day 8. Up to 5 years before, he was misusing with ecstasy and alcohol. At admission, his urine toxicology specimen was positive for cannabis only. Over the first few days of pregabalin intake, he was feeling increasingly relaxed, emphasizing that the pregabalin effects were “very similar to those of cannabis.” As a result, over the first 4 weeks or so, he gradually increased the dosage up to 1500 mg, feeling as being “under the influence of an anesthetic,” and “very light.” To achieve both a quicker and more intense effect, he also tried to smoke the crushed pregabalin tablets. He allegedly obtained the extra pregabalin tablets from a friend. Over time, however, he developed an intense muscle pain, as he had “severely torn his leg muscle.” Although unfortunately, CPK levels were not made available, a tentative diagnosis of myositis was made, with causes different from pregabalin intake having been ruled out by both clinical interview and full medication review. The Naranjo Probability Scale7 indicated a probable relationship between pregabalin intake and the onset of myositis. Pregabalin was gradually discontinued, and benzodiazepines were introduced to control the observed increase in both anxiety and craving levels. The muscular pain disappeared over a week. DISCUSSION The case reports here described suggest that pregabalin experimenters might be profiled as individuals with a history of recreational polydrug, including ecstasy, misuse and, as such, confirming previous observations.5 Pregabalin dosages reported here, especially in case 1, were clearly a reason of concern and certainly in excess of the advised daily maximum level (eg, 600 mg).8 Overall, the misuse of pregabalin mostly seem to occur orally, but intravenous, rectal (“plugging”), and “parachuting” (emptying the content of the capsule into a pouch) self-administration techniques have been described as well.5 However, patient 2 allegedly tried to smoke an unconfirmed amount of pregabalin crushed tablets, a technique, which to the best of our understanding, had never been reported before. In both cases, the patients were started with pregabalin for medical reasons. However, because of the rapid developme
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conversely, olanzapine high-dosage has been anecdotally reported as the 'ideal trip terminator/modulator' (49)(50).”
From Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs (2020) · cites this paper as [49]
Citations
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914
Schifano, F., D’Offizi, S., Piccione, M., Corazza, O., Deluca, P., Davey, Z., Di Melchiorre, G., Di Furia, L., Farré, M., Flesland, L., et al. (2011) · Psychotherapy and Psychosomatics · doi:10.1159/000321079 · Cited by 187
Self-citationSchwan, S., Sundström, A., Stjernberg, E., Hallberg, E., & Hallberg, P. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-010-0853-y · Cited by 169
Drugs on the web; the Psychonaut 2002 EU project
Schifano, F., Deluca, P., Baldacchino, A., Peltoniemi, T., Scherbaum, N., Torrens, M., Farré, M., Flores, I., Rossi, M., Eastwood, D., et al. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.035 · Cited by 112
Self-citationPregabalin Abuse, Dependence, and Withdrawal: A Case Report
Grosshans, M., Mutschler, J., Hermann, D., Klein, O., Dreßing, H. R., Kiefer, F., & Mann, K. F. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09091269 · Cited by 108
Martinotti, G., Di Nicola, M., Frustaci, A., Romanelli, R., Tedeschi, D., Guglielmo, R., Guerriero, L., Bruschi, A., De Filippis, R., Pozzi, G., et al. (2010) · Addiction · doi:10.1111/j.1360-0443.2009.02792.x · Cited by 83
Potential for pregabalin abuse or diversion after past drug-seeking behavior.
Filipetto, F. A., Zipp, C. P., & Coren, J. S. (2010) · PubMed · Cited by 81
Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial
Martinotti, G., Di Nicola, M., Tedeschi, D., Andreoli, S., Reina, D., Pomponi, M., Mazza, M., Romanelli, R., Moroni, N., De Filippis, R., et al. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109102623 · Cited by 81
Internet pharmacies and online prescription drug sales: a cross-sectional study
Littlejohn, C., Baldacchino, A., Schifano, F., & Deluca, P. (2005) · Drugs Education Prevention and Policy · doi:10.1080/0968763042000275326 · Cited by 80
Self-citationHadley, S. J., Mandel, F. S., & Schweizer, E. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111405360 · Cited by 66
Efficacy and safety of pregabalin in alcohol dependence
Martinotti, G., Nicola, M. D., Tedeschi, D., Mazza, M., Janiri, L., & Bria, P. (2008) · Advances in Therapy · doi:10.1007/s12325-008-0066-2 · Cited by 55
Pregabalin in the discontinuation of long‐term benzodiazepines' use
Oulis, P., Konstantakopoulos, G., Kouzoupis, A. V., Masdrakis, V. G., Karakatsanis, N. A., Karapoulios, E., Kontoangelos, K. A., & Papadimitriou, G. N. (2008) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.937 · Cited by 39
Westin, A. A., & Strøm, E. J. H. (2010) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.10.0986 · Cited by 15
Research works printed but not linked: 1
- Nymdelger, 2007, Pregabalin: a neuromodulator for the treatment of neuropathic pain, generalized anxiety disorders and cystic fibrosis syndrome., Medizin Monatssch Pharmazeuten, 30, 396
Cited by
Abuse and Misuse of Pregabalin and Gabapentin
Evoy, K. E., Morrison, M. D., & Saklad, S. R. (2017) · Drugs · doi:10.1007/s40265-017-0700-x · Cited by 410
How addictive are gabapentin and pregabalin? A systematic review
Bonnet, U., & Scherbaum, N. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.08.430 · Cited by 281
Misuse and Abuse of Pregabalin and Gabapentin: Cause for Concern?
Schifano, F. (2014) · CNS Drugs · doi:10.1007/s40263-014-0164-4 · Cited by 250
Self-citationChiappini, S., & Schifano, F. (2016) · CNS Drugs · doi:10.1007/s40263-016-0359-y · Cited by 189
Self-citationAbuse Potential of Pregabalin: A Systematic Review
Schjerning, O., Rosenzweig, M., Pottegård, A., Damkier, P., & Nielsen, J. (2016) · CNS Drugs · doi:10.1007/s40263-015-0303-6 · Cited by 162
Metadata
- Authors
- Carrus, D., & Schifano, F.
- Affiliations
- University of Hertfordshire (GB)
- ORCID
- Schifano, Fabrizio
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2012-12
- Volume
- 32
- Issue
- 6
- Pages
- 839-840
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2058884859
- Cited by
- 49
- References
- 13
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 1 · 2022: 4 · 2021: 4 · 2020: 6 · 2019: 2 · 2018: 2 · 2017: 7 · 2016: 4 · 2015: 4 · 2014: 4 · 2013: 7
- FWCI
- 6.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- University of Hertfordshire Research Archive (University of Hertfordshire) (submittedVersion)
- Funders
- European Commission
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- recreational drug use, myositis, GABA analogues, benzodiazepine withdrawal, antisocial personality disorder, cannabis use, alcohol consumption, neuropathic pain, polydrug use
- MeSH terms
- Pregabalin, Adult, gamma-Aminobutyric Acid, Humans, Male, Myositis, Smoking, Prescription Drug Misuse
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.